# A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

> **NCT02914275** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 2250 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Seqirus Quadrivalent Inactivated Influenza Vaccine
- **BIOLOGICAL:** Comparator Quadrivalent Inactivated Influenza Vaccine

## Key facts

- **NCT ID:** NCT02914275
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-27
- **Primary completion:** 2017-03-09
- **Final completion:** 2017-08-11
- **Target enrollment:** 2250 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914275, "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT02914275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*